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Metastasis remains the cause of 90% of deaths from solid tumors. The metastasis alters 
the cell microenvironment, enters the circulation, and colonizes a distant organ. Migration 
of brain cancer cells involves a heterogeneous microenvironment that consists of stromal 
cells, signaling molecules, and various extracellular matrix (ECM) configurations. The 
significant interactions between stromal cells and tumors cells create an environment 
where brain cancer cells can grow and spread. The complexity and heterogeneity of 
tumors and their microenvironment challenge the study of metastasis and its treatment.  
 
In the past three decades, a group of chemoattractants and their receptors have been 
associated to cause cancer cell migration. Chemoattractants, such as growth factors and 
chemokines, are believed to be secreted by neighboring cells, diffuse and generate 
concentration gradients that are sensed by the central nervous system-derived tumor 
cells (Medulloblastoma). These cells migrate away from primary tumors to settle in the 
brain or the spinal column. Researchers believed that the brain tumor invasion is caused 
by soluble factors that stimulate directional (chemotaxis) or random (chemokinesis) tumor 
cell motility. Despite of studies in cell migration, the role of chemoattractants is still 
understudied due to the highly complex microenvironment. Previous research published 
on migration of breast cancer, fibroblast, and glioblastoma have demonstrated that growth 
factor concentration gradients play an important role in cell motility. Our research group 
has previously illustrated the importance of the spatial-temporal gradient profiles of 
chemoattractant on cell migration. However, it is not well understood the impact of 
gradients on cell motility, and understanding them has been a long-term focus of cell 
migration research. 
 
                                                                    ii 
Historically, several traditional migration assays (Boyden, Zigmond, Dunn chambers; and 
micropipette) have been widely used for cell migration studies. However, these assays 
lack the ability to maintain and control chemical concentration gradients or allow the real-
time quantification of chemoattractants gradients around individual cells over time. 
Recently, microfluidic devices have been applied to chemotaxis studies. These 
microsystems can generate well-defined and stable chemical concentration gradients at 
low fabrication costs, small reagent volumes, and high-throughput experimentation. 
 
This work has utilized a microfluidic platform, the Bridged μLane System, to examine the 
in vitro migratory response of medulloblastoma (MB)-derived cells to external signaling of 
Epidermal Growth Factor (EGF) and the stromal cell-derived factor 1-alpha (SDF-1). Our 
microfluidic system can generate defined and controlled concentration gradient fields, 
which are categorized into five orders of magnitude along different positions of the 
microchannel. Within these gradient fields, the fraction of motile cells, directionality and 
cell path length of MB cells under EGF and SDF-1 stimulation were determined. The 
cellular responses to external signaling of EGF, hepatocyte growth factor (HGF), platelet-
derived growth factor (PDGF-BB), and SDF-1 via motility studies were examined as well 
as the relative receptor expression for EGF-R, c-MET, PDGFR-BB, and CXCR4, 
respectively. MB cells were observed to have the potential to travel from high to low ligand 
concentration gradient fields. MB-derived cells responded strongly to EGF in a dosage 
and gradient-dependent manner with increased EGF-R activation. In addition, high 
concentration gradient fields of EGF caused more cells to move longer distances in a 
directional dependent manner as opposed to SDF-1. This work provides evidence that 
EGF and its receptor play an important role in MB migration than previously documented.
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CHAPTER 1. INTRODUCTION 
 
1.1 Characteristics of malignant pediatric brain tumors:  
 
 
Medulloblastoma (MB) is the most aggressive pediatric brain tumors that accounts for 
about 13%-20% of all childhood tumors, with over 400 cases diagnosed in USA annually 
(33, 44, 49). MB arises in the posterior cranial fossa, near the brainstem and cerebellum, 
parts of the brain that are responsible for cardiac and breathing cycle, and motor control 
(movement, balance, and coordination), respectively. MB tumors are characterized by a 
high rate of metastasis to the brain and the spinal cord (17). Clinical studies and magnetic 
resonance imaging (MRI) have shown that MB spreads from the cerebellum down to the 
spinal column (45, 72). MB first invades meninges, or the tissue that lines the brain and 
spinal column, before gaining access to the cerebrospinal fluid (CSF) (51, 68, 72). There, 
metastasis results from tumor cells that drop into the CSF and tend to “seed” in any part 
of the spine. MB cells migrate on the spinal column via combination of two-dimensional 
(2D) movements or crawling on the surface of the spine, and three-dimensional (3D) 
movements or infiltrating in the spinal column causing paralysis (11, 16, 23, 43).  
 
MB cell migration is believed to be derived from so-called cancer stem-like cells (CSCs), 
which are the most aggressive cell type with marked capacity for proliferation, self-
renewal, and differentiation in many malignant tumors, as previously reported in in-vivo 
and in-vitro studies (15, 45) (see Figure 1.1). CSCs are stimulated by complex and 
dynamic extracellular microenvironments responsible for the heterogeneity of brain 
tumors (45, 47, 60, 67). As a heterogeneous disease, MB is composed of 4 subtypes 
characterized by unique molecular and genomic features: Wingless (WNT), Sonic 




survival rate with 5-year survival chances being less than 30% while WNT achieves an 
overall 5-year survival rate of 60–85% (33, 49, 60). While multimodality therapeutic 
approaches including surgery, radiation, and chemotherapy have significantly increased 
survival rates, these treatments lead to threatening side effects such as impairments in 
language, attention, memory, motor functions, and major endocrinal deficiencies (26, 52, 
56, 62). 
Figure 1.1. Schematic of the origin of brain tumors: development gone wrong. 
Adapted from (1). (A) During normal development, stem cells give rise to neurons, 
oligodendrocytes, and Astrocytes. Genetic alternations occur within these cells that can 
lead to the rise of malignant brain tumors. (B) Medulloblastoma cells originate in the 
cerebellum, from granule neuron precursor cells (GNPCs), upon uncontrolled activation 
of Sonic Hedgehog (Shh) signaling pathway.  
 
 
1.2 Mechanisms of Medulloblastoma migration:  
The migration of cancer cells within the central nervous system (CNS) is decidedly 
complex, affected by cellular interactions with heterogeneous extracellular matrix (ECM) 




migration of MB-derived cells along gradients of bimolecular concentration, i.e. 
chemotaxis, remains incompletely understood (1). Chemoattractants can be secreted by 
neighboring healthy or oncogenic cells to stimulate MB migration away from the primary 
tumor (1). In particular, MB migration towards the vasculature is believed to fuel high 
chemoresistivity and recurrence (1). 
 
MB chemotaxis has been largely examined with respect to biomolecules that stimulate 
the migration in glioblastoma (GL), the most common brain tumors diagnosed in adults 
(28). An established body of research has demonstrated GL sensitivity to external 
signaling initiated by PDGF, HGF, and EGF, and to a lesser extent SDF-1 (6). PDGF 
inhibitors have been reported to decrease the ability of both GL and MB to cross the 
blood-brain barrier and target tumor cells (4, 9, 21, 27, 63), while c-MET inhibition has 
been widely documented in MB and GL cells that do not respond to external signaling via 
migration (38, 69). Further, it has been reported that overexpression of the engineered 
EGF-R homolog, ErbB2, can increase MB and GL migration in-vitro (7, 12, 20), while 
transactivation of EGF-R via PDGFR-B activity was able to enhance migration, survival, 
and proliferation of MB and GL cells in-vitro (4, 20). Drugs such as c-met inhibitors 
(SGX523) (29, 66), PDGFR inhibitors (Sunitinib) (3, 46), CXCR4 inhibitors (Plerixafor) 
(13, 58), EGFR inhibitors (Tarceva) (18, 25), etc., have all been extensively studied to 
observe MB and GL tumor growth, invasiveness and metastasis. In addition, Estradiol 
(17beta-estradiol) occurs in the body and brain, and mediates different functions (5). The 
binding of estradiol to estrogen receptor, and non-steroid receptor (e.g. EGFR) activates 
downstream signaling events (RAS and PI3K) (5, 20). Estrogen influences the growth 




noncompetitive antagonist of CXCL12 binding to CXCR4) showed inhibition of MB tumors 
and decrease in tumor proliferation (53). Research has also shown that the binding of 
CXCL12 to CXCR4 induces intracellular signaling pathways initiating signals related to 
chemotaxis, cell survival and/or proliferation, increase in intracellular calcium, and gene 
transcription (53, 58). EGF has been understudied in MB tumor growth and metastasis. 
However, our group has shown in previous studies that EGF concentration gradients 
modulate chemotaxis of MB-derived cells in a dose-dependent manner via EGFR (20). 
 
1.3 Microfluidic devices and Chemotaxis: 
 
Microfluidic devices have been widely studied in the last two decades and have become 
one of the most commonly used bench top method of various fields of research (14, 30). 
Microfluidics started out as technique for specific applications and tool in fundamental 
chemical, biological and pharmaceutical research (32). Whitesides and coworkers have 
revolutionized this field by developing and introducing poly-dimethylsiloxane (PDMS) to 
the field of microfluidics (48, 55, 64). Due to the physical (transparent), mechanical 
(flexibility), and chemical (non-toxic and biocompatible) properties of PDMS, this material 
is widely used to make devices for biological applications (55). PDMS has been adopted 
to make microfluidic devices capable of generating concentration gradients for use in 
chemotaxis experiments (42, 64).  
 
Chemotaxis is defined as the directed cell migration by soluble gradients of 
chemoattractants (growth factors and chemokines). It is the driving force behind cellular 
movements that occur during inflammatory immune responses, wound repair, 




important field of biomedical studies consists in identifying chemoattractant concentration 
gradients that maximize cell migratory behavior. Several groups have previously used 
time-lapse video-microscopy to observe cell polarity, motility, and ability to detect and 
respond to gradients of chemoattractants. In response to uniform stimulation with 
chemoattractants, the cells become elongated and polarized, with clear leading and 
trailing ends, and their random motility increases (chemokinesis) (24, 31, 57). When cells 
are confronted with a chemoattractant concentration gradient, they undergo chemotaxis, 












Figure 1.2. Illustration of chemoattractant gradients on cell motility. When cells 
sense chemoattractant gradients, the polarized ones migrate toward high 
chemoattractant concentration (indicated by intensity of red color). The front (F) and back 





In the past decades, different researchers have used conventional methods to measure 
cell migration, but these techniques have been found limited to study chemotaxis. Thus, 
microfluidic devices have been implemented to study cell chemotaxis.  
 
1.3.1 Traditional migration assays: 
In the past 50 years, various conventional bioassays have been developed and utilized 
to examine cell migration induced by chemoattractant molecules (41, 50). However, most 
of these methods lack the ability to maintain and control chemoattractant concentration 
gradients, and do not allow real-time quantification of cell migration at the single-cell level.  
 
1.3.1.1 Boyden Assay: 
Boyden chamber assays or transwell assays have been used as a high-throughput 
screen of multiple ligand concentrations and incubation times since 1962 (41, 50). It is 
composed of a cylindrical cell culture insert (filter) installed into a well of a cell culture 
plate. The insert and well are separated by a porous membrane with a defined pore size 
(See Figure 1.3 (A)). Cells are seeded on top of the insert in serum-rich media, while 
serum-free media mixed with chemoattractant is placed in the well. Motile cells move 
through the porous membrane toward the chemoattractant, then these are stained and 
quantified. In this assay, chemoattractant gradients are nonlinear, transient, and difficult 
to determine. In addition, Boyden assays do not allow researchers to image cells in real 







1.3.1.2 Zigmond Assay: 
Developed in 1972, this commonly-used migration assay allows researchers to visualize 
cells during migration. The Zigmond chamber consists of a slide with two closely spaced 
rectangular reservoirs connected by a bridge (41, 50) (See Figure 1.3 (B)). A 
concentration gradient is established along the length of the bridge by filling one reservoir 
with media and the other with a chemoattractant (61, 71). The cells attached to the 
chamber can be visualized using a microscope when these cells migrate towards the 
chemoattractant. However, several problems with this method include gradients poorly 












Figure 1.3. Schematic of conventional migration assays. (A) Boyden assay, (B) 
Zigmond chamber, (C) Dunn chamber, and (D) Micropipette assay. Adapted and modified 







1.3.1.3 Dunn Chamber: 
The Dunn Chemotaxis Chamber was designed to improve optical properties and long-
term stability of the gradient in 1997 (41, 70). It consists of a glass slide with two 
concentric rings ground into the center of the slide with a depth half the thickness of the 
slide (See Figure 1.3 (C)). The inner ring of the chamber is filled with serum-rich medium 
while the outer ring chamber is filled with serum-free medium mixed with chemoattractant 
(10, 50). Then, a linear diffusion gradient is developed and maintained for few hours. 
However, this method does not allow to measure quantitatively the ligand gradients at 
different positions over time.  
 
1.3.1.4 Micropipette:  
The micropipette assay has been used to generate chemoattractant gradients by the 
release of these molecules from micropipettes (54). This method provides a localized 
source of diffusible molecules for in-vivo and in-vitro studies (See Figure 1.3 (D)). This 
method allows direct visualization of cells but it is very irreproducible and uncontrolled 
due to the angle, size, and flow rate injected (54).  
 
1.3.2 Types of microfabricated devices 
Unlike conventional cell migration assays, microfluidic gradient devices can create 
defined concentration gradients of chemoattractants. In addition, these devices allow 
more efficient and quantitative evaluations of cell migration in spatial-temporal domains 
of complex chemoattractant fields that better mimic in-vivo conditions (39). There are two 





1.3.2.1 Flow-based microfluidics: 
These devices create stable gradients based on controlled mixing (laminar flow) of 
different chemical reagents. Particularly, mixing of laminar flows occurs across the width 
of the microfluidic channel which allows to precisely control stable chemical concentration 
gradients across the channels (41). In addition, the gradient profile is relatively stable over 
long distances along the channel. Some examples of flow-based microfluidics are three 
channel microfluidic devices (19, 22, 41), in which linear gradient is generated in the 
absence of flow or T-channel device that monitors chemotaxis perpendicular to the 
direction of the fluid flow (19), were developed subsequently. 
 
1.3.2.2 Non-flow based microfluidics:  
These devices generate time-evolving or stable chemical concentration gradients in a 
flow-free environment. They use large chemical reservoirs, and allow chemoattractants 
and media to mix by free diffusion in microfluidic channels (41). Because of the small 
dimensions of microfluidic channels compared to the volume of chemical sources, the 
development of gradient over time can be controlled and gradients can be established at 
the equilibrium state of diffusion (41). The use of 2D or 3D substratum between the 
reservoirs and mixing channels, better mimic the tissue environment and thus are more 
physiological relevant for particular cell types (41). Some examples of flow-free 
microfluidics are digital microfluidics such as the free-flow electrophoresis device, which 







1.3.2.3 The Bridged µLane System: 
Our group developed a microfluidic device, called the Bridged μLane System, a user-
friendly platform to study cell migration. One of the advantages of this microsystem is that 
it creates steady-state concentration gradients of chemoattractants along the length of 
the microchannel as a function of time that approximates the microenvironments 
generated in-vivo. In addition, it allows us to examine and predict local ligand gradients 
at any cell position over time. This system contains 2 layers of a silicon-based organic 
polymer (PDMS). The top layer is composed of a bridge channel in between two 
chambers while the bottom layer consist of a microchannel (cross sectional area: 100µm 
x 100µm) in between two reservoirs (see Figure 1.4). The elastomeric PDMS is bonded 
to a glass slides which serves as a bio-compound coating used to coat surface with 











Figure 1.4. Image of elastomeric PDMS microchannel (μLane). The first layer of 
PDMS is composed of two chambers while second layer of PDMS consists of a 




By controlling the bulk flow, we are able to determine different chemoattractant 
concentration gradients across cells, and to observe single-cell migration during 
experimental conditions. The bulk flow is caused by inertia during the loading of 
chemoattractants. Previously, our group measured this bulk flow (as laminar flow) with a 
low Reynolds number of less than 10-3, and a Peclet number between 10 and 50 when 
molecules between 6 to 10KDa are used (EGF or Dextran) (36). The large chambers’ 
volume along with bridge channel eliminate hydraulic pressure difference within 
microchannel due to chamber volume differences. Also, these large chambers’ volume 
maintain stable chemoattractant concentration gradients within the microchannel. The 
transport of chemoattractant or ligands within the microchannel is predicted by the 1-
Dimensional convective-diffusion equation via computational models (36).    
 
Previously, our group has used this microfluidic device to measure cell proliferation, 
survival, and migration of fibroblast cells (37), glioblastoma cells (2), retinal progenitor 
cells (59), and Medulloblastoma cells (20) to concentration gradients of extracellular 
signaling molecules. This microsystem follows into the flow-free microfluidic devices 
category. It does not required fluidic control tools such as pressure pumps, peristaltic 
pumps, or valves to maintain steady-state concentration gradients of chemoattractant 
molecules. The computational models along with experimental measurements allow us 
to measure quantitatively local chemoattractant concentration and gradients and observe 
cell responses to temporal ligand gradients, which greatly benefit cell migration studies 






1.4 Overview:  
 
In this thesis, we will discuss the uniqueness of medulloblastoma migration and 
summarize the main in-vitro and in-vivo studies (Chapter 1). We will describe in detail all 
methodologies and materials carried out by the authors for this thesis (Chapter 2). The 
aim of this thesis is to identify new therapeutic targets for Medulloblastoma (MB) 
metastasis towards controlled microenvironments of chemotactic agents previously 
believed insignificant for MB migration (Chapter 3). First, the in-vitro cellular responses of 
MB-derived cells to external signaling of Epidermal Growth Factor (EGF), hepatocyte 
growth factor (HGF), platelet-derived growth factor (PDGF-BB), and the stromal cell-
derived factors 1-alpha (SDF-1) will be described via motility and immunocytochemistry 
studies (Chapter 3). Likewise, the in-vitro migratory responses of MB-derived cells to 
similar concentrations of EGF and SDF-1, and controlled concentration gradient fields 
within our microfluidic device will be described in detail (Chapter 3). Lastly, in Chapter 4, 
a summary of main findings as well as the development of a new microfluidic system will 
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CHAPTER 2. MATERIALS AND METHODS 
 
 
2.1 Medulloblastoma Cell Culture:  
 
In vitro cell culture was maintained using the human medulloblastoma (MB)-derived Daoy 
cell line (ATCC, Cat. No.HTB-186) (3-5, 8). Daoy cells were cultured with Eagle's Minimal 
Essential Medium (EMEM) (VWR, Cat. No.12001-582) supplemented with 45 mL of 10% 
fetal bovine serum (VWR, Cat. No.45000-734), 5mL of 1% Penicilin-Streptomycin (VWR, 
Cat. No.45000-650), and 10mL of 2% L-glutamine (VWR, Cat. No.45000-676). Daoy cells 
were detached from their substratum using Trypsin EDTA 1X (VWR, Cat. No. 45000-
660). To grow intact monolayers, these cells were plated onto sterile plasma-treated 
polystyrene tissue culture flasks (VWR, Cat. No.BD353136), and incubated at 37ºC with 
95% humidity and 5% CO2. Daoy cells were maintained at a density of 1.5x106 cells/mL. 
The cell medium was changed every 2 days, and cells were passaged every 3 days when 
reached at least 80% confluence.  
 
2.2 Boyden Chamber Assay for Cell Migration: 
 
The Boyden chamber assay or transwell assay was used to measure the number of MB 
cells that migrated towards different nano-concentrations of EGF, HGF, PDGF, and SDF-
1. After splitting a confluent flask with Daoy cells, the cell pellet was disrupted to obtain 
individual cells by utilizing a cell strainer (VWR, Cat. No. 102095-532) for use with 50 mL 
centrifuge tubes, and cells were resuspended twice through the cell strainer. Daoy cells 
were seeded in the upper compartment and were allowed to migrate through the porous 




5% CO2 incubator as displayed in Figure 2.1 (A) and (B). The cell culture filters (VWR, 
Cat. No.62406-198) were inserted into wells of a 24-well plate, and were utilized to build 
up the Boyden chamber assay. Once MB cells were at least 80% confluent, approximately 
1x106 cells/mL were seeded in 300μl of EMEM complete medium in each upper chamber, 
while 700μl of serum-free medium (EMEM only) was loaded in each lower chamber. 
Figure 2.1. Schematic of transwell assay. (A) The assay consists of a filter with a 
porous mebrane inserted into well. (B) Growth factors diffuse upwards and cause 
migration of cells on the underside of porous membrane. (C) Daoy cells with stained 
nuclei and cytoplasm on the underside of the porous membrane and imaged for migration 
analysis. Scale bar = 100μm 
 
 
For all migratory measurements, growth factor solutions were diluted in EMEM serum-
free medium using serial dilutions. These consisted of concentrations of 1, 10, 100, and 
1000 ng/mL of EGF (Life Technologies Corporation, Cat. No.E3476); HGF (R&D 
Systems, Cat. No.2207-HG/CF); PDGF-BB (R&D Systems, Cat. No.220-BB-010); and 




between the two compartments was fixed and stained with fixative solutions I (VWR, Cat. 
No. B4132-11A), which stained the cell cytoplasm and nuclei as shown in Figure 2.1 (C). 
Residues from the fixative solutions in the inner and outer part of the filters were removed 
carefully by using double-tip cotton swabs (VWR, Cat. No. 10806-004) without touching 
the bottom surface of the porous membrane where Daoy cells were located. The 24-well 
plates were covered with aluminum foil and stored in the refrigerator at 40ºF. Following, 
the number of cells that have migrated to the underside of the membrane was determined 
by using the checkerboard analysis (1, 2). 
 
2.2.1 Imaging and Analysis:  
 
Transmitted light microscopy images of Daoy cells were obtained using an inverted 
microscope equipped with short and long range objectives (Nikon TE2000) and a cooled 
CCD camera (CoolSNAP EZ CCD Camera, Photometrics, Tucson, AZ). Daoy cells were 
located within five areas of the culture inserts and counted upon each filter using the 
checkerboard pattern (1, 3, 10) for a total of five rectangular locations. These data were 
used to gather representative cell counts per nano-concentration of the growth factors 
measured (n=12 per nano-concentration).  
 
2.3 Immunocytochemistry of Growth Factor Receptors:  
Daoy cells were plated at a concentration of 1x105 cells/mL in EMEM complete, on 
borosilicate glass well plates (Lab-Tek, Cat. No.155383). In each confocal well, 500μL of 
cell solution was added to fully cover the bottom of each well. Thus, Daoy cells were 
allowed to attach to the wells during approximately 2 hours of incubation at 37°C in 5% 




Aldrich, Cat. No.X100) in 0.1% of Bovine Serum Albumin (BSA) in Phosphate Buffered 
Saline (PBS), and 1% blocking solution (BSA in PBS). After Daoy cells were fully attached 
to each well of the confocal plates, cells were exposed to ligand concentrations, which 
showed the largest numbers of motile cells in the Boyden chamber assay results. Prior to 
the immunocytochemistry assay, Daoy cells were exposed to 5 minutes of stimulation of 
100ng/mL EGF (Life Technologies, Cat. No.PGH0311), 100ng/mL SDF-1 (Life 
Technologies, Cat. No.PHC1364), 10ng/mL HGF (Life Technologies, Cat. No.PHG0324), 
and 100ng/mL PDGF-BB (Life Technologies, Cat. No.PHG0044). Then, the supernatant 
was aspirated and each well was rinsed 3 times with 500μL of 1X PBS (Sigma-Aldrich, 
Cat. No.D8537). Each well was fixed using 10% paraformaldehyde (Sigma-Aldrich, Cat. 
No.HT501128) for 10 minutes, and rinsed twice with 1X PBS. The samples were 
permeabilized using 500μL of 0.1% Triton X-100 in BSA-PBS solution for 10 minutes, 
then blocked for 60  minutes with 1% BSA in 1X PBS, and rinsed twice with 500μL of the 
same blocking solution.  
 
Then, samples were exposed to the primary antibody for each receptor studied for 2 hours 
at room temperature (22°C): 5μg/mL anti-EGFR (Life Technologies, Cat. No.700308), 
5μg/mL anti-CXCR4 (Life Technologies, Cat. No.35-8800), 2μg/mL anti-c-Met (Millipore, 
Cat. No.07-2242), and 3μg/mL anti-PDGFR (Life Technologies, Cat. No.701142). These 
primary antibodies were diluted in Dako Antibody diluent with background reducing 
components (Dako North America Inc, Cat. No.S302281-2) at a concentration of 4μg/mL. 
Each plate was covered with 500μL of primary antibody solution diluted in Dako reducing 
background solution (same volume for secondary antibody). After primary antibodies 




secondary anti-rabbit IgG (Millipore, Cat. No.AP132F) was for used EGFR, c-Met, and 
PDGFR samples, while a fluorescent anti-mouse secondary antibody (Millipore, Cat. 
No.MAB1976) was used for CXCR4 samples. All samples were exposed to the secondary 
antibody (diluted in Dako antibody diluent solution) at a concentration of 4μg/mL for 30 
minutes at room temperature (22°C), and then rinsed twice with 300μL of 1X PBS. Finally, 
two drops of nuclear staining (Life Technologies, Cat. No.R37605) per well was added 
for 20 minutes at room temperature (22°C), and then the samples were rinsed twice with 
300μL  of 1X PBS and 700μL of glycerol were added (Life Technologies, Cat. No.15514-
011) for preservation, and confocal plates were covered with aluminum foil and stored in 
the refrigerator at 40ºF prior confocal measurements. 
 
2.3.1 Imaging and Analysis: 
Fluorescent imaging of Daoy cells was performed using Zeiss LSM 710 confocal 
microscope with a 63x oil immersion objective. The National Institutes of Health (NIH) 
ImageJ software was utilized to measure the fluorescence intensity of basal membrane 
receptors (EGF-R, c-Met, PDGFR-BB, and CXCR4) using an average over the entire cell 
area.  
 
2.4 Bridged μLane System: 
 
The bridged μLane is a microfluidic system utilized to image the real-time migratory 
responses of individual Daoy cells within microenvironments of defined gradient profiles 
of growth factor solutions (EGF and SDF-1). It is fabricated from Polydimethylsiloxame or 
PDMS via contact photolithography (1, 6, 7). In brief, the system consists of two layers of 




of PDMS consists of a closed microchannel of 100μm-width and 1.3cm-length (0.1μL), 
which connects the source (SRR) and the sink (SKR) reservoirs (9μL each). The second 
layer of PDMS consists of the source (SRC) and the sink (SKC) chambers (170μL each), 
connected by an open bridge channel which sustains the hydrostatic equilibrium of the 
system (6). Both SRC and SKC are vertically and fluidically connected with SRR and 
SKR, respectively.  
Figure 2.2. The μLane system used to measure cell migration.  (A) Image of top view 
of the first layer PDMS bonded onto a glass slide. Two 9-nL reservoirs are connected by 
a microchannel of 13mm in length and 150µm in diameter. (B) Image of top view of 
second layer PDMS bonded to the first layer. The source and sink chambers are 
connected by a bridge channel.  
 
 
2.4.1 Microfabrication Techniques: 
Soft lithography, also known as micromolding was used to replicate the structure of Bridge 
μLane system using elastomeric polydimethylsiloxane or PDMS molds (Fisher Scientific, 
Cat. No. NC9644388). The base and curing agent were mixed at particular ratio (10:1, 
respectively), and then degassed using a vacuum desiccator for 40 minutes to remove 
bubble formed due to mixing (see Figure 2.3). When bubbles were removed from the 




solidify in a convective oven at 85°C for 1 hour. Then, the double-layered PDMS with 
patterns was detached from the mold, and ready to proceed with bonding.  
Figure 2.3. Microfabrication of bridged μLane system. (A) Sylgar-184, base and 
curing agent in liquid state, were mixed and poured into a 50-mL centrifuge tube, then 
placed in (B) a vacuum desiccator to remove bubbles. (C) Two aluminum cast masters 
were used to make the first and second layer of the μLane system. (D) The liquid-state 
PDMS without bubbles was poured around the aluminum mold. (E) The microchannel 
chambers were created by using 0.1-10μL micro pipet tips while elastomeric PDMS was 
inside a convection oven. (F) Elastomeric PDMS mold of μLane system prior bonding to 
a pre-cleaned glass slide.  
 
 
One critical step in microfabrication is the bonding of the PDMS channels to a glass slide. 
The glass slides were chemically cleaned with Nano-Strip (VWR, Cat. No. 10135-756), 
and left in solution overnight. The next day, these glass slides were rinsed with deionized 
water and dried with a nitrogen tank (Airgas USA, Cat. No.007761). Bonding of PDMS 




Product, Inc., Model BD-10A). The bottom surface of microchannel or first PDMS layer 
that contains microchannel was exposed to 30 seconds of ozone while the pre-cleaned 
glass slide was exposed to 30 seconds of ozone before bonding both surfaces together.  
 
2.4.2 Operation and Experimental Set up of Bridged μLane System: 
 
In order to mimic the cell microenvironment, μLanes were coated with 10-μg/mL of laminin 
(Becton, Dickinson and Company, Cat. No.354232), which was allowed to gel for one 
hour at room temperature (25°C) under sterile conditions. In 2D coating experiments, the 
unbound laminin was aspirated from the channels. A cell solution (1x106 cells/mL) was 
manually injected into the SRR, microchannel, and SKR using a 1-mL syringe (VWR, Cat. 
No.BD309659). Daoy cells were allowed to attach, then cell culture media was used to fill 
the SRR, microchannel, SKR, SRC, SKC, and the bridge channel (see Figure 2.4).  
 
The bridged μLane system operates by manually inserting ligand solutions (growth 
factors) drop-wise into the SRC until the solution makes contact with the cell culture media 
solution within the bridge channel and the SKC, to initiate the molecular transport within 
the system via uniaxial bulk convection and diffusion (6). The small differences in the 
density of the reagents and in the liquid levels in the SRR and SKR generate hydrostatic 
pressure differences that initiate an ultra-low bulk flow within the microchannel in the first 
layer (6). This diminutive bulk flow facilitates the transport of ligand solutions from the 
SRR to the SKR, to accelerate the time required to attain a steady-state gradient profiles 






Figure 2.4. Schematic of Bridged μLane system. Schematic of the entire system, side 
view, showing loaded cell within SKR and SRR reservoirs, and adhered along the 
microchannel. Ligand solutions are loaded into the SRC, and transported to SKR to reach 
steady-state concentration distribution.  
 
 
2.4.3 Mathematical Modeling: 
 
The bridged μLane system has been computationally modeled via finite-element analysis 
(FEM) in Matlab 7.7 (MathWorks, Natick, MA) and verified experimentally previously by 
our group (3, 6, 7). Previous experimental measurements carried out by our group with 
fluorescently labeled Dextran solutions (MW ~10 KDa) were added to the μLane system 
to measure diffusivity within the microsystem across three different channel sections over 
time for achieving steady-state transport (3, 6). The diffusivity (0.82 x 106 cm2/sec) and 
the bulk velocity (0.37 μm/sec) values of fluorescently labeled Dextran, previously 
measured by our group (6) were utilized to solved the two-dimensional Fick’s law of 
convective-diffusion equation with MatLab to generate the EGF or SDF-1 concentration 
distribution along the length of the entire microchannel. The evolution of the gradient 
distribution along our microsystem (see Figure 2.5 (A)), displayed a non-linear 
distribution as a function of time and position across the microchannel. In addition, both 




after 18 hours (6, 9) (see Figure 2.5 (B)).Note that the ligand concentration at 18 hours 
in the region of the channel closest to the SKR is approximately 63% of the starting EGF 
or SDF-1 concentration. 
Figure 2.5. Modeled concentration gradients of bridged μ-Lane system. (A) 
Normalized EGF concentrations plotted against increasing distance from the source 
reservoir (SRR) to the sink reservoir (SKR) as a function of time (3, 6, 7, 9). Note that the 
ligand concentration at 18 hours in the region of the channel closest to the SRR is 
approximately 63% of the starting EGF concentration. (B) Normalized concentration 
distribution of EGF and SDF-1 along the length of microchannel. Concentration gradients 
were defined by five regions with different order of magnitude in the microchannel.  
 
The initial EGF or SDF-1 concentration within the source chamber, sink reservoir, 
microchannel and source reservoir was set to 0-ng/mL, since no ligand solution was 
manually inserted. The initial ligand concentration within the source chamber was set to 
100-ng/mL to reflect the sample concentration used during experiments. These boundary 





                                                                                                                Equation (1) 
                                                                    
Where C (ng/mL) is ligand concentration (EGF or SDF-1), t (hours) is total time of 
experiment (24 hours), u (μm/sec) is fluid velocity or bulk velocity, and D (cm2/s) is the 
diffusion coefficient, or diffusivity, of the ligand solution.  
 
2.4.4 Imaging and Analysis 
Transmitted light image data was analyzed using Nikon software (Nikon Instrument 
Element 2.30 with 6D module, Morrell Instrument Company Inc., Melville, NY). In addition, 
Image J was utilized to track Daoy cells and process images with Chemotaxis and 
Migration Tool plugin (ImageJ 1.46r). Chemotaxis parameters such as the center of mass 
(averaged point of all cell end points) and the maximum accumulated distance (cell path 
length) were generated from the tracking software. Bright field images of the 
microchannel were automatically captured every hour for 24 hours at every 1000 microns 
in the y-direction of the µLane, followed by cell tracking (ncells~180 cells) and analysis. 
Also, the cell tracking software was used to develop Wind-Rose plots of cell trajectories 
in response to EGF and SDF-1 gradient fields, over 24 hours. 
 
2.5 Statistical Analysis: 
One-way ANOVA and Post Hoc Test (Tukey) using IBM SPSS Statistics Program (IBM 
Corp., Released 2011, Version 20.0. Armonk, NY) were utilized to analyze the statistical 
significance across growth factors. The p-values < 0.05 were considered statistically 




evaluated using standard deviation and unpaired student’s t-test at a 95% confidence 
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Medulloblastoma (MB) is a malignant pediatric brain tumor known for its aggressive 
metastatic potential. Despite the well-documented migration of MB cells to other parts of 
the brain and spinal column, MB chemotaxis is poorly understood. Herein, we examined 
the in vitro migratory and cellular responses of MB-derived cells to external signaling of 
Epidermal Growth Factor (EGF), hepatocyte growth factor (HGF), platelet-derived growth 
factor (PDGF-BB), and the stromal cell-derived factors 1-alpha (SDF-1). Experiments 
utilized transwell assays and immunocytochemistry to identify receptor activation in MB 
migration, and used a microfluidic platform to examine directionality, trajectory, and 
gradient-dependence of motile cells. Data illustrates that MB-derived cells respond 
strongly to EGF in a dosage and gradient-dependent manner with increased EGF-R 
activation, and show that high EGF gradient fields cause an increased number of cells to 
migrate longer directed distances. Our results provide evidence that EGF and its receptor 
play an important role than previously documented in MB chemotactic migration and 



















Medulloblastoma (MB) is a family of highly-invasive tumors most commonly diagnosed in 
the pediatric central nervous system (7, 28, 38, 41, 50). While clinical treatments have 
more than doubled the overall 5-year survival rate to upwards of 60% (16, 28, 44, 52), 
additional therapies are needed to target the aggressive MB migration that is 
uncharacteristic of other brain tumors, but is a hallmark of MB recurrence, metastasis, 
and radioresistivity (13, 21, 24, 28, 41, 55, 61, 70). The migration of cancer cells within 
the CNS is decidedly complex, affected by cellular interactions with heterogeneous 
extracellular matrix (ECM) as well as mixed cellular responses to concentration fields of 
biomolecules (1, 14, 19, 60, 65). However, the mechanisms behind the migration of MB-
derived cells along CNS gradients of biomolecular concentration, or chemotaxis, remain 
understudied and incompletely understood (14, 28). Particular complexities arise in MB, 
because chemoattractant fields that rouse cells away from primary tumors can be 
secreted by healthy or transformed distant and neighboring cells (1, 3, 9, 34, 58, 76). 
Further, clinical studies have illustrated that the spread of MB cells occurs predominantly 
to the spinal column via a combination of two-dimensional (2D) and three-dimensional 
(3D) movements (6, 51, 67, 77, 83). Such spreading results from tumor cells that drop 
into the cerebrospinal fluid and tend to seed in parts of the spine (53, 74, 77, 79, 84). As 
a result, the movement of MB cells on the surface of the spinal column can be examined 
on 2D substrata to plausibly physiologically approximate the metastatic behavior of these 
pediatric brain tumors.  
 




assays (36, 54, 78) to report numbers of cells that become motile in response to external 
signaling from growth factors, such as Epidermal Growth Factor (EGF) and Platelet-
Derived Growth Factor (PDGF) (4). However, chemotaxis is becoming more-commonly 
examined via the physical microenvironment of the cell, where dynamic concentration 
fields facilitate ligand-receptor bindings which initiate signal transduction cascades (1, 8, 
59). Here, precise manipulation of the cell microenvironment has been facilitated by the 
wide-adaptation of benchtop microfluidic devices (26, 27, 29), which enable multifaceted 
evaluation of cell migratory behaviors in lieu of cell numbers alone. A large number of 
laboratories have demonstrated concentration- and concentration gradient-dependent 
behavior of non-cancerous cells, such as fibroblasts (33), retinal progenitor cells (69) and 
keratinocytes (64), as well as tumors found in breast (57), colon (17) and CNS cancers 
(2).  Our own laboratory has illustrated that select populations of cells derived from CNS 
tumors can respond acutely via migration to ultra-low concentration gradients of select 
chemoattractants (2, 14, 33), while others have shown greater chemotactic response with 
specific dosage (3, 49, 56). Microfluidic analysis is, thus, well positioned to meaningfully 
aid in the development of migration-targeted therapies for MB via insight of migratory 
parameters relevant to metastasis, such as cell distance traveled, motility, gradient-
sensitivity, ECM interaction and numerous others.  
 
In this work, we examine MB migratory behavior in response to external signaling from 4 
of the most extensively studied chemoattractants of CNS tumors using benchtop assays 
and microfluidics: Epidermal Growth Factor (EGF), Platelet-derived Growth Factor 
(PDGF), Hepatocyte Growth Factor (HGF), and Stromal Derived Growth Factor (SDF-1 




behavior in EGF fields, which are able to guide MB along longer migration distances with 
superior directionality and increased receptor activation. These results distinguish EGF 
as a principal molecule with meaningful potential impact as an anti-migratory therapeutic 
to MB metastasis.  
 
3.2 MATERIALS AND METHODS 
Cell culture 
In vitro cell culture was maintained using Daoy cell line (ATCC, Cat. No.HTB-186) (14, 
60), Eagle's Minimal Essential Medium (EMEM) (VWR, Cat. No.12001-582) 
supplemented with 10% fetal bovine serum (VWR, Cat. No.45000-734), 2% L-glutamine 
(VWR, Cat. No.45000-676) and 1% Penicilin-Streptomycin (VWR, Cat. No.45000-650). 
Intact monolayers were maintained and harvested cells were seeded onto sterile 
polystyrene tissue culture flasks (VWR, Cat. No.BD353136). MB cells were incubated at 
37 ºC with 5% CO2 with cell medium changed every 2 days. Cell migration experiments 
were initiated with cells that were inserted into microchannel after MB cells reached 80% 
confluence. 
 
Cell Migration Assay 
The Boyden chamber assay (2, 14) was used to measure the number of MB cells that 
migrated towards different concentrations of external growth factors. This widely-used 
assay consists of two compartments filled with EMEM medium and separated by an 8 
micron-porous membrane (VWR, Cat. No.62406-198), as shown in Figure 3.1.A. MB 
cells were seeded in the upper compartment and were allowed to migrate through the 




Approximately 1x106 cells/mL were seeded in 300μl of EMEM complete medium (EMEM 
with FBS) in each upper chamber, while 700μl of serum-free medium (EMEM only) was 
pipetted into each lower chamber. Lower chambers also contained concentrations of 1, 
10, 100, and 1000 ng/mL of EGF (Life Technologies Corporation, Cat. No.E3476); HGF 
(R&D Systems, Cat. No.2207-HG/CF); PDGF-BB (R&D Systems, Cat. No.220-BB-010); 
and finally SDF-1 (PreporTech, Cat. No.250-20A). All growth factor solutions were diluted 
in EMEM serum-free medium using serial dilution. After 6 hours of incubation, the 
membrane was fixed and stained with fixative solutions (VWR, Cat. No. B4132-11A), 
which stained the cell cytoplasm and nuclei. The number of cells that migrated to the 
underside of each membrane was determined by using the convectional checkerboard 
analysis (2, 14, 82).  
  
Immunostainning of Receptors 
MB cells were plated at a concentration of 1x103 cells/mL in EMEM complete, on 
borosilicate glass well plates (Lab-Tek, Cat. No.155383). The cells were incubated for 2 
hours at 37°C in 5% CO2 to facilitate attachment. Adhered cells were exposed to ligands 
at concentrations that resulted in the largest numbers of motile cells in the transwell assay 
results.  At 37°C, each cell plate was exposed to 5 minutes of: 100ng/mL EGF (Life 
Technologies, Cat. No.PGH0311), 100ng/mL CXCL12 (Life Technologies, Cat. 
No.PHC1364), 10ng/mL HGF (Life Technologies, Cat. No.PHG0324), and 100ng/mL 
PDGF-BB (Life Technologies, Cat. No.PHG0044). The supernatant was then aspirated 
and each well was rinsed 3 times with 0.5 mL phosphate buffered saline solution (PBS), 
(Sigma-Aldrich, Cat. No.D8537). Each well was fixed using 10% paraformaldehyde 




samples were permeabilized using a 1% solution of Triton-X (Sigma-Aldrich, Cat. 
No.X100) and 0.1%BSA in PBS solution for 10 minutes, then blocked for 60 minutes with 
1% BSA in PBS blocking solution and rinsed twice with the same blocking solution.  
 
Samples were then exposed to the primary antibody for each receptor studied for 2 hours 
at 22°C: 5μg/mL anti-EGFR (Life Technologies, Cat. No.700308), 5μg/mL anti-CXCR4 
(Life Technologies, Cat. No.35-8800), 2μg/mL anti-c-Met (Millipore, Cat. No.07-2242), 
and 3μg/mL anti-PDGFR (Life Technologies, Cat. No.701142). Each well was rinsed 3 
times with 1% BSA blocking solution. A fluorescent secondary anti-rabbit IgG (Millipore, 
Cat. No.AP132F) was used for EGFR, c-Met, and PDGFR samples, and a fluorescent 
anti-mouse secondary antibody (Millipore, Cat. No.MAB1976) was used for CXCR4 
samples. All samples were exposed to the secondary antibody at a concentration of 
5μg/mL for 30 minutes at 22°C, and then rinsed twice with blocking solution. Nuclear 
staining (Life Technologies, Cat. No.R37605) was performed for 20 minutes at 22°C, after 
which the samples were rinsed twice with PBS and covered in glycerol (Life Technologies, 
Cat. No.15514-011) for preservation. In addition, the expression of EGFR was measured 
at different time points of 0, 14, 22, 36, and 42 hours. The immunocytochemistry assay 
was performed as described above using goat-anti mouse IgG secondary antibody (Life 
Technologies, Cat. No. A-11005) for EGFR. 
 
Bridged μLane and Experimental Set up 
Our microfluidic device, the μLane, was utilized to image the real-time migratory 
responses of individual MB cells within microenvironments of defined EGF and SDF-1 




convection and diffusion to achieve controlled chemical concentration gradients over 
time, as described previously (2, 32, 33). This mass transfer mechanism termed as 
convective-diffusion has been widely-studied by several groups for bioengineering 
applications, to determine the transport of differently sized solutes and proteins through 
the walls of capillaries (11, 12, 20) and arteries (25, 30, 39, 66, 80), skeletal muscle fibers 
(31, 35, 45), and intervertebral discs (18, 62, 63). The two-dimensional mass transport of 
ligands within the microsystem was modeled via finite-element-analysis (FEM) in Matlab 
7.7 (MathWorks, Natick, MA) and verified experimentally as described previously by our 
group (32, 33).  
 
The framework of the μLane system consists of two layers of Polydimethylsiloxame 
(PDMS) (Fisher Scientific, Cat. No.NC9644388) bonded to a glass slide using ozone gas. 
The first layer of PDMS consists of a closed microchannel of 100µm-width and 1.3cm-
length with a volume of 0.1μL, which connects two fluidic reservoirs of 9μL each, called 
the source (SRR) and the sink (SKR) reservoir. The second layer of PDMS consists of 
two chambers of 170μL each, called the source (SRC) and the sink (SKC) chamber, 
connected by an open, hemispherical bridge channel to maintain the hydrostatic 
equilibrium of the system (32, 33, 69). Both chambers are vertically and fluidically 
connected with both reservoirs (Figure 3.3).  
 
The μLane system works by using the larger volumes of the SRC, SKC and bridge 
channel on the second layer of PDMS to generate concentration gradients within the 
smaller volumes of the SRR, SKR and microchannel on the first layer (14, 32, 33, 69). 




SRR, SKR, SRC, SKC, and the bridge channel. The ligand solutions (EGF or SDF-1) are 
then manually inserted drop-wise into the SRC until the solution makes contact with the 
cell culture media solution within the bridge channel and SKC to initiate the molecular 
transport within the system. The small differences in the density of the reagents and in 
the liquid levels in the SRR and SKR generate hydrostatic pressure differences that 
initiate an ultra-low bulk flow within the microchannel in the first layer (32, 33, 69). This 
minuscule bulk flow was measured to be 0.37 μm/sec using fluorescent beads, as 
described previously (32). Such a low bulk flow facilitates the transport of ligand solutions 
from the SRR to the SKR, to accelerate the time required to attain a steady-state gradient 
profile of ligand solutions along the 13-mm length of the microchannel. In the absence of 
this bulk flow, the transport of our reagent via diffusion alone would require over 470 hours 
to reach a steady-state distribution within the length of the μLane instead of the 18 hours 
measured, as reported by our group (14, 32). We note that because the time required for 
the overall system to reach steady-state is much larger than the time needed for steady-
state concentration gradients to be generated within the μLane system alone. Thus, the 
operation of the system is ‘best’ described as ‘quasi-steady-state’ (5, 10, 40, 68, 71, 73). 
However, because this work focuses exclusively on smaller time scales of the 
microchannel only, the term steady-state would be used for simplicity. Mathematical 
models of reagent transport within our μLane system were performed via MatLab to 
determine the steady-state concentration distribution as seen in Figure 3.4.A. The initial 
EGF or SDF-1 concentration within the SKC, SKR, microchannel and SRR was set to 0-
ng/mL, as per absence of ligand. The initial ligand concentration within the SRC was set 
to 100-ng/mL to reflect the sample concentration used during experiments. These 




                                                                                                    (1) 
Where C (ng/mL) is ligand concentration, t (hours) is time, u (μm/sec) is fluid velocity, and 
D (cm2/s) is diffusion coefficient, or diffusivity, of the reagent molecule. Experimental 
validation was also performed using fluorescently labeled Dextran (~ MW 10KDa), to 
confirm steady-state is reached in our system after 18 hours, and is maintained for several 
days (14, 32).  
 
For our experiments, the μLane system was coated with 10-μg/mL of laminin (Becton, 
Dickinson and Company, Cat. No.354232) (14, 60), and allowed to gel for one hour at 
room temperature (25°C) under sterile conditions. Unbound laminin was aspirated and 
cells were manually seeded into the microchannel using a 1-mL syringe (VWR, Cat. 
No.BD309659). A cell solution (1x106 cells/mL) was injected into the SRR and SKR. Cells 
were allowed to adhere and visibly spread prior to the initiation of the experiment as 
illustrated in Figure 3.3.D. Finally the bridge channel was loaded with EMEM complete 
medium to connect the SRC and SKC, initiating the system. In this work, EGF (100-
ng/mL) or SDF-1 (100-ng/mL) was individually loaded drop-wise into the SRC and 
allowed to reach steady state in the microchannel for 18 hours at 37°C (32), prior to 
imaging of MB cell migration within this precise biochemical environment; therefore, all 
data is collected within steady-state concentration gradient fields for 24 hours. Our group 
has previously showed that MB cells migrate and proliferate in vitro until 72 hours in the 












One-way ANOVA and Post Hoc Test (Tukey) were used to analyze the data using IBM 
SPSS Statistics Program (IBM Corp., Released 2011, version 20.0. Armonk, NY). A one-
way ANOVA test at a 95% confidence interval was performed for statistical significance 
across growth factors. The Post Hoc Test (Tukey) was performed to determine the 
disparity among different groups. Only p-values <0.05 were considered statistically 
significant. Unpaired student’s t-test at a 95% confidence interval was implemented to 
determine significance of relative receptor expression using IBM SPSS Statistics Program 
(IBM Corp., Released 2011, version 20.0. Armonk, NY).  
 
Imaging and Processing 
Transmitted light microscopy images were obtained using an inverted microscope (Nikon 
TE2000) and a cooled CCD camera (CoolSNAP EZ CCD Camera, Photometrics, Tucson, 
AZ) with a 20X objective magnification (Nikon Plant 20X, Morrell Instrument Company 
Inc., Melville, NY). Fluorescent imaging was performed using Leica CLSM confocal 
microscope and a Zeiss LSM 710 confocal microscope, both at 63x magnification with oil 
immersion objective. Image J was utilized to track cells and process images (Chemotaxis 
and Migration Tool plugin (ImageJ 1.46r) (14, 15). Fluorescence intensity was measured 
using an average over the entire cell area via ImageJ. Transmitted light image data was 
analyzed using Nikon software (Nikon Instrument Element 2.30 with 6D module, Morrell 
Instrument Company Inc., Melville, NY) and ImageJ (NIH) Software. Bright field images 
of the microchannel were automatically captured every hour for 24 hours at every 1000 
microns in the y-direction of the µLane, followed by cell tracking (ncells~180 cells) and 




of cell trajectories in response to EGF and SDF-1 gradient fields, over 24 hours. 
 
3.3 RESULTS 
This work examined the migratory and cellular responses of MB-derived cells in response 
to external signaling from EGF, HGF, PDGF-BB, and SDF-1.  
 
Motility Studies 
The first set of experiments measured the average numbers of MB-derived cells that 
migrated toward different concentrations of EGF, HGF, PDGF-BB, and SDF-1 through 
transmembrane assays, as illustrated in Figure 3.1 and Table 3. 1. As seen, numbers of 
motile cells were statistically different in response to signaling from different 
concentrations of EGF and HGF when compared to controls (i.e. no ligand). Further, a 
mid-level concentration of 100-ng/mL of EGF was observed to attract the largest numbers 
of motile cells overall (Fig. 3.1.B.1).  By contrast, the number of MB cells that migrated in 
response to external signaling from concentrations of SDF-1 did not exhibit statistical 
difference from controls or each other (Fig. 3.1.B.4). Similarly, the number of motile MB 
in response to signaling from different concentrations of PDGF-BB did not display 

























Figure 3.1. Migration of MB-derived cells to different concentrations of selective 
chemotactic ligands. (A1) Schematic of transwell assay with motile cells attached to the 
underside of the porous membrane. (A2) Stained nuclei and cytoplasm of motile MB-
derived cells toward different concentrations of (B1) EGF, (B2) HGF, (B3) PDGF, and 
(B4) SDF-1. The control groups indicate number of cells that migrated towards serum-
free medium. An asterisk (*) indicates statistically significant data with p-values <0.05 







Table 3.1. Average numbers of MB-derived cells that migrated in transwell assays 
towards different concentrations of examined growth factors. Values were experimentally 
measured and are shown with mean and standard deviation. (*) denotes growth factor 












Relative Receptor Expression 
 
The basal expression levels of the respective receptors were then compared against their 
activation levels upon ligand stimulation. Confocal images in Figure 3.2 illustrate 
differences in cellular distribution of activated receptors, as well as differences in 
fluorescent intensity after ligand stimulation. As seen, basal receptor expression appears 
to be uniformly distributed throughout the cell cytosol, with lowest intensities measured 
for EGF-R. Upon ligand activation, receptor expression is increased, but remains largely 
distributed throughout the cytosol. However, EGF-R expression is also observed to be 
acutely concentrated along the outer cell membrane. Analysis of fluorescence intensity 
then represented relative receptor expression levels upon ligand-stimulation. MB 
stimulated with EGF exhibited the highest increase in receptor expression for EGF-R, 
with a 3.5-fold increase in intensity over basal EGF-R expression measured in 
unstimulated controls (Fig. 3.2.A). By contrast, the expression of CXCR4, the receptor 
for SDF-1, was approximately 2-fold higher than its basal intensity levels in cells 
unstimulated with ligand (Fig. 3.2.B), while no statistical difference was measured 
between the activation levels of c-Met, the receptor for HGF (Fig. 3.2.C), and control cells, 






























Figure 3.2. Receptor activation within motile MB-derived cells. Immunocytochemistry 
of basal receptor expression of MB cells without ligand stimulation to (A1) EGF, (B1) SDF-
1, (C1) HGF, and (D1) PDGF-BB. Receptor activation post-stimulation with (A2) EGF, 
(B2) SDF-1, (C2) HGF, and (D2) PDGF-BB. The expression level of receptor following 
ligand stimulation of (A3) EGFR, (B3) CXCR4, (C3) c-Met, and (D3) PDGFR-BB 
normalized to basal control levels. Scale bars are 100µm. An asterisk (*) indicates 





Migratory response to controlled concentration and gradient fields 
The migratory behavior of MB was next examined using our microfluidic system, called 
the μLane and shown in Figure 3.3, for real-time cell imaging and analysis. The transport 
of EGF and SDF-1 along the μLane was modeled computationally, and verified 
experimentally as previously reported by our group (32). The system produced a range of 
concentration gradients along the microchannel length at steady-state, as shown in 
Figure 3.4.A (14, 33). Concentration gradients of this study are defined as the average 
difference in growth factor concentration (ng/mL) along the microchannel length (mm). 
Five orders of concentration gradient, G1-G5, were delineated along the microchannel as 
illustrated in Figure 3.4.A: 10+1<G1<100 ng/(mL.mm), 100<G2<10-1 ng/(mL.mm), 10-
1<G3<10-2 ng/(mL.mm), 10-2<G4<10-3 ng/(mL.mm), and 10-3<G5<0. The lowest gradient, 
G5, was located near the source reservoir (growth factors only) and occupied 
approximately 1-mm-length of the microchannel, while the highest gradient, G1, was 
located near the sink reservoir and occupied an approximate, 3-mm-length of 
microchannel. Concentration gradients, G2, G3, and G4, occupied the remaining 9-mm-
length of microchannel (distance in between the source and the sink reservoirs) with 
approximately 4 mm, 3 mm and 2 mm segments, respectively. Note, the core distributions 
of EGF and SDF-1 along the microchannel are very similar to one another given their 
respective molecular weights of 6.045 KDa and 7.9 KDa, and hence only one 
representative gradient distribution is shown. Further, cells were evenly distributed along 


























Figure 3.3. The μLane system and MB migratory responses.  (A) Schematic of the 
bridged μLane system, showing cells inserted within the sink (SKR) and source (SRR) 
reservoir, and adhered along the microchannel. Chemotactic agents (e.g. EGF, SDF-1) 
are loaded into the source chamber (SRC), and transported to SKR to reach steady-state 
concentration distribution. (B) Top view image of the first layer PDMS bonded onto a glass 
slide. Two 9-nL reservoirs are connected by a microchannel of 13mm in length and 
100µm in diameter. (C) Top view image of second layer PDMS bonded to the first layer. 
The source (SRC) and sink (SKC) chambers are connected by a bridge channel. (D) Raw 
data image of motile MB cells within μLane system at (D1) source reservoir, (D2) mid 


























Figure 3.4. Concentration distribution along μLane and number of motile cells. (A) 
Concentration profile of EGF and SDF-1 along 13-mm microchannel length of μLane 
system. Concentration gradients are identified by five orders of magnitude in the 
microchannel: 10+1<G1<100 ng/(mL.mm), 100<G2<10-1 ng/(mL.mm), 10-1<G3<10-2 
ng/(mL.mm), 10-2<G4<10-3 ng/(mL.mm), and 10-3<G5<0 ng/(mL.mm). (B) Fraction of MB-
derived cells observed to respond via migration to the different concentration gradient 




The migration of MB-derived cells in response to the different concentration gradient fields 
of EGF and SDF-1 were described using three parameters: (1) Fraction of motile cells, f, 
defined as the number of cells that migrated more than two cell diameters in the μLane, 
normalized by the total number of cells within the channel; (2) cell directionality, D, defined 
as the percentage of cells whose net center of mass was preferably towards the positive, 
x-displacement or along the gradient direction; and (3) Average cell path length, PL, 
defined as the total distance traveled by cells.  
 
First, the average percentage of motile cells along the entire microchannel was similar for 
both growth factors. Table 3.2 shows that 72.82% of MB became motile in response to 
EGF signaling, while an average 67.3% of MB became motile in response to SDF-1 
concentration fields. Values of motile fraction varied with gradient fields, fG1-fG5, for both 
EGF and SDF-1, as shown in Table 3.3. As seen, the highest fraction of MB cells became 
motile when exposed to higher concentration gradient fields of EGF, G1 (f1=28.3%) and 
G2 (f2=18.6%), followed by decreasing percentages of motile cells within lower gradient 
fields of EGF, G3 (f3=11.9%), G4 (f4=10.3%) and G5 (f5=3.7%). Similarly decreasing 
fractions of cells were seen to migrate in response to concentration gradient fields of SDF-
1, with highest fractions at G1 (f1=18.2%) and G2 (f2=20%), followed by significant 
decreases in the fraction of motile cells at concentration gradient fields G3 (f3=13.8%), G4 
(f4=8.7%) and G5 (f5=6.5%). As shown in Figure 3.4.B, the fraction of nonmotile cells 
was 27.2% and 32.8%, when exposed to similar concentration gradients of EGF and 
SDF-1, respectively. Statistical significance was observed between concentration 
gradient fields of EGF while no statistical significant difference was found across the 










Table 3.2. Migratory parameters of MB-derived cells along the µLane system in response 
to concentration gradients generated by 100ng/mL of EGF and 100 ng/mL of SDF-1, 
respectively. Values were experimentally measured and shown as percentages, means 
and standard deviations. (ncells ~ 180 cells for each ligand). 
 
 
Table 3.3. Migratory parameters of MB-derived cells in response to gradient fields, G1-
G5, generated by of 100ng/mL of EGF or SDF-1 along the µLane system, respectively. 
Fraction (f) and directionality (D) of motile cells shown as percentages of total cell 
numbers. Average maximum cell path lengths (PL) shown with mean and standard 
deviation. (ncells ~ 180 cells for each ligand).  
 
 
Next, the average directionality of motile MB was determined by examining individual cell 
trajectories. The term directionality was previously introduced by our group as the ratio of 
the number of cells whose centroids migrated more than 80 µm to the total number of 




concentration gradient fields were optically tracked within the μLane system to generate 
the representative Wind-Rose plots shown in Figure 3.5.A. Note that although cell 
trajectories are each positioned at a common origin for comparison, cell paths were 
measured along all microchannel segments, exposed to all gradient fields G1-G5. 
Representative trajectories illustrate that cells migrated preferentially towards lower 
concentration gradients of EGF (i.e., towards the right). By contrast, SDF-1 fields resulted 
in MB migration that was both towards and away from lower SDF gradients without 
preference. The directionality of motile cells along the entire microchannel was higher for 
cells stimulated with EGF (61.6%) than SDF-1 (44.2%), shown in Table 3.2. As seen, cell 
directionality within specific gradient fields, DG1-DG5, decreased with decreasing gradient 
for both EGF and SDF-1, shown in Table 3.3. EGF DG1 indicates that 28.3% of motile 
cells migrated directionally when exposed to G1 of EGF (i.e. within the first 3mm of 
channel length), while SDF DG1 denotes that only 18.4% displayed directional migration 
for the same gradient field of SDF-1.  The highest fraction of MB cells directionality was 
reported at higher concentration gradient fields of EGF, DG1 (28.3%) and DG2 (15%), 
followed by decreasing percentages for directionality within lower gradient fields of EGF, 
DG3 (7%), DG4 (8.6%), and DG5 (2.7%). Similarly decreasing fractions of directionality were 
reported in response to concentration gradient fields of SDF-1, with highest fractions at 
DG1 (18.4%) and DG2 (10.5%), followed by decreasing fractions of directionality at DG3 



























Figure 3.5. Motility of MB-derived cells in the μLane system. (A) Representative 
trajectories of cells that migrated in response to 100ng/mL of EGF and 100 ng/mL of SDF-
1 stimulation. Three cell paths are shown in dashed for EGF and three in solid for SDF-
1, 24 hours post steady-state. Note that concentration gradients decrease from left to 
right within the μLane. (B) Maximum accumulated distance of motile cells stimulated by 
concentration profiles generated by using 100ng/mL of EGF and 100 ng/mL of SDF-1, 





In addition, Wind-Rose plots display the average maximum cell path length, PL, of motile 
cells tracked along the entire microchannel. Using this data, 32% of motile MB migrated 
distances greater than 200 microns (or 20 cell-diameters) when exposed to EGF gradient 
fields, as seen in Figure 3.5.B. By contrast, 97.3% of cells exposed to SDF-1 gradients 
migrated distances less than 200 microns. MB within our μLane system in the absence 
of growth factors or concentration gradients (i.e. controls) displayed migration distances 
between 50 and 200 microns (14). As shown, increasing percentages of cells were seen 
to migrate in response to higher gradient fields of EGF. A larger percentage of motile MB 
were observed in response to G1 fields of EGF at every distance, while only cells exposed 
to G1 migrated the longest distances greater than 300 microns. In comparison, MB 
exposed to lower gradient fields of SDF-1 (G3-G5) exhibited the longest migration. 
Notably, zero cells were observed to migrate less than 100 microns when exposed to any 
EGF gradient field G1-G5, while zero cells were seen to migrate greater than 300 microns 
when exposed to any SDF-1 gradient fields G1-G5. 
 
3.4 DISCUSSION 
The chemotactic migration of MB-derived cells has been surprisingly understudied 
despite its well-known metastatic potential and aggressive invasion into the brain and 
spinal cord (14, 43). Our study is among the first to examine and compare the migratory 
responses of MB to dosage-dependent signaling from EGF, HGF, PDGF-BB, and SDF-
1, the most widely-acknowledged chemoattractants of CNS tumor cells (37). The first set 
of experiments utilized conventional transwell assays to illustrate that MB migration was 
most concentration-dependent to EGF signaling. As shown in Figure 3.1, MB exhibited 




dosage-independent responses to PDGF and SDF-1 signaling. Further, EGF simulated 
the migration of approximately twice the number of MB cells than did PDGF, HGF, or 
SDF-1. Results from immunocytochemistry support the strength of MB chemotactic 
response to EGF signaling, as activation of its receptor, EGF-R, was two times larger 
than activation of other respective receptors. While strong MB chemotactic response to 
EGF signaling is consistent with previous findings from our group and others (14, 42), it 
is most significant here because it is signaling from SDF-1, rather than EGF, that has 
been reported as the strongest MB chemoattractant (56). Inhibitor AMD310, which 
cleaves CXCR4, has been reported to decrease MB tumor growth in mouse xenografts, 
chemotaxis and proliferation (56). However, in vivo use of EGF-R inhibitors such as 
Tarceva and Gefitinib have reported no changes in motility of cells derived from glioma 
(47), and non-small-cell lung cancer (23), and thus, were minimally used on MB. We 
contend that MB chemotactic response may not have been measured most meaningfully 
in the past, which has stymied development of anti-migratory therapies for MB metastasis.  
For this reason, we used microfluidic systems to more precisely study MB migratory 
responses using parameters relevant to metastasis. 
 
Using the μLane system, we were able to image real-time cell behavior in response to a 
wide range of concentrations and gradients of EGF and SDF-1, and distinguish directed-
migration of chemotaxis. MB migratory behavior was observed to be concentration 
gradient-dependent for both EGF and SDF-1 signaling, as the fraction of motile cells 
decreased with decreasing concentration gradient in both cases. However, motile MB 
traveled longer distances within the μLane in response to EGF signaling, with an average 




to signaling from SDF-1. Further, cell trajectories illustrated an MB directional bias 
towards decreasing EGF gradients not present with SDF-1 signaling, with 18.3% of cells 
migrating towards decreasing EGF gradients compared to 15.3% of MB in response to 
decreasing SDF-1 gradients. Importantly, this behavior was observed along the entire 
μLane length, for cells exposed to all concentration gradient fields, G1-G5. Here, the cell 
directionality compared to other methods provides insight into whether MB cells 
stimulated with ligand solutions (EGF or SDF-1) followed a directional migration along 
gradient fields. Other methods to measure cell migration include the persistence length 
and average velocity to determine the chemotactic sensitivity of stable gradients in 3D 
(22, 46, 72, 75). While the persistence length provides the ratio of the net distance 
traveled to the total distance, it would not report the number of cells that migrate along 
ligand concentration gradients, which is highly significant to studies developing migration-
targeted therapies for tumors of the CNS.  
 
This consistent MB behavior illustrates that EGF signaling from high concentration 
gradients initiates the most motile MB, and further enables cells to travel the longest 
distances. MB cells were seen to migrate towards increasing ligand concentration, which 
also corresponds to decreasing EGF gradient fields in our system. This response is 
significant because it reflects MB sensitivity to high concentration gradients (G1-G2), 
which were generated via much greater nonlinear changes in ligand concentration as 
compared to low gradient fields (G3-G5). Previous work from our group has illustrated 
keen abilities of MB to migrate in larger numbers in response to increasing EGF 
concentration via pERK signaling (14). In that work, MB cells were seen to travel out of a 




study, we now demonstrate that MB can become less motile when exposed to signaling 
from increasing concentration but diminishing EGF gradient fields.  
 
Data from the current study highlights the high fraction of motile MB in response to high 
concentration gradients of EGF. These results have high clinical interpretation, as they 
point to high gradient fields and low concentration fields as optimal for MB migration. This 
is an in vivo scenario where paracrine signaling from neighboring cells initiate the most 
MB migration, such that cell displacement diminishes as cells approach the signaling 
source, where gradients are low and concentration is high. In addition, our findings may 
aid clinical development of anti-migratory therapeutics with the potential to inhibit MB 
metastasis along the spinal column via EGF signaling. 
 
3.5 CONCLUSION 
In summary, our results illustrate that MB migration is both concentration and 
concentration gradient-dependent in response to EGF signaling. Further, our findings 
illustrate that high gradient fields of EGF result in the largest number of motile cells, which 
travel long distances, and in a highly directional manner towards decreasing EGF 
gradients. These findings point to EGF as a viable molecule for migration-targeted 
therapies for MB.  
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CHAPTER 4. CONCLUSIONS AND FUTURE WORK RECOMMENDATIONS 
 
4.1 Summary 
In the research of the central nervous system-derived tumor cells migration described 
thus far, we have (1) investigated migration patterns in response to external signaling of 
EGF, HGF, PDGF-BB, and SDF-1 via traditional migration assays; (2) examined the basal 
membrane receptor expression of EGF-R, c-Met, PDGFR-BB, and CXCR4 via 
immunocytochemistry; (3) determined how medulloblastoma cells migrated in response 
to steady-state gradients of EGF and SDF-1 using a microfluidic platform. Our findings 
illustrate that EGF produced (a) the largest number of motile cells, (b) the highest basal 
membrane receptor activation (EGF-R), (c) the most directionality towards increasing 
gradients, and (d) the largest accumulated distance traveled.  
 
These results have a significant clinical impact, since EGF is identified as a new target 
for medulloblastoma migration at low concentration and/or high concentration gradient 
fields of EGF. These findings might contribute to the development of anti-cancer 
therapeutics drugs (EGFR inhibitors or small molecules kinase inhibitors) (4, 5, 17, 18) 
that can impede medulloblastoma metastasis along the spinal column via EGF-R 
signaling.  
 
4.2 Future Direction 
 
In this section, we will discuss the future experiments and methodologists used to further 
investigate medulloblastoma migration. We propose two sets of examinations to be completed in 




similar characteristics as the µLane, and (2) combination of different growth factors to better mimic 
medulloblastoma microenvironment during cell migration.  
 
4.2.1 Development of a new microfluidic device 
The µLane system has been used as a quantitative platform to generate precise 
concentration-gradients fields of individual chemoattractants to study single-cell 
migration. However, we propose to modify the µLane system by adding three inlets or 
reservoirs into the microsystem (See Figure 4.1.A). This design maintains the same 
dimensions as the µLane system (length and area of channel) but requires pressure 
pumps to ensure mixing of ligand concentrations by diffusion through the microchannel. 
This diffusion leads to linear ligand concentration gradients at steady-state (1), which can 
be precisely predicted using computational models. Using this device, we will be able to 
observe cells responses while tracking their change in displacement along the 1.3-cm 
length of microchannel. This might provide another venue to investigate cell responses 
and dynamics to chemical gradients diffusing in a 2-Dimensional microenvironment as 
previously utilized by other researchers (3, 9, 11, 13, 14).  
 
4.2.2 Combination of different growth factors 
The most studied growth factors in glioblastoma metastasis are EGF, HGF, and PDGF 
which have been demonstrated to be involved in cell migration, proliferation, and invasion 
(2, 6, 7). We are interested in examine the different signal pathways triggered by these 
growth factors, which could affect cell functions. The mechanism by which combination 





The new version of µLane would allow us to determine the migratory behavior of 
medulloblastoma cells under the simultaneous stimulation of three chemoattractants to 
better mimic the physiological microenvironment in which these cells metastasize.  This 
microsystem will rely on fluidic control tools such as pressure pumps to generate and 
maintain concentration gradients for biological experiments. Another avenue we want to 
continue to explore the migratory behavior of central nervous system-derived tumor cells 
by employing two-dimensional biomimetic extracellular matrices such as laminin and 
matrigel, utilizing this new microsystem to generate stable gradients of chemoattractants 



























Figure 4.1. Schematic of microfluidic device composed of three inlets. (A) Top view of 
microfluidic device with similar dimensions as µLane system (L=1.3cm; A=100x100µm]. (B) Top 
view of microdevice displaying the loading in each inlet (three most studied chemoattractants in 
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